ArticleHuman cell2009
Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer.
Article in Human cell, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 14 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Pooled it
- The association between single nucleotide polymorphisms and ovarian cancer risk: A systematic review and network meta-analysis.Cancer medicine · 2023Pooled it
- Association between genetic polymorphisms and endometrial cancer risk: a systematic review.Journal of medical genetics · 2020Pooled it
- Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis.Medicine · 2018Pooled it
- Pooled it
- Relationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2016Pooled it
- Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- MDM2 SNP309 variation increases cervical cancer risk among Asians.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.Journal of experimental & clinical cancer research : CR · 2013Pooled it
- The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls.PloS one · 2013Pooled it
- MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis.Medical oncology (Northwood, London, England) · 2011Pooled it
- Pooled it
- MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.BMC cancer · 2011Pooled it
- Promising Terpenes as Natural Antagonists of Cancer: An In-Silico Approach.Molecules (Basel, Switzerland) · 2019Article
- Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4.Cancers · 2019Article
- Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.BMC medical genetics · 2015Article
- TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women.Medical oncology (Northwood, London, England) · 2014Article
- Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.Oncology reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A functional T to G germline polymorphism in the promoter region of murine double-minute 2 homolog single nucleotide polymorphism 309 (MDM2-SNP309) has been reported to profoundly accelerate tumor formation, suggesting that it may also represent a powerful cancer predisposing allele. In this study, MDM2-SNP309 was examined in a total of 400 blood samples from 108 normal, 88 cervical, 119 endometrial and 85 ovarian cancer cases using two independent polymerase chain reaction assays for each allele. When the MDM2-SNP309 genotype was classified into two subgroups of TT+TG and GG, the GG genotype was associated with an increased risk for the development of endometrial cancer (odds ratio [OR]= 1.91, 95% confidence interval [CI] = 1.05 to 3.47) compared with the TT+TG genotype (P = 0.0353). The G allele also increased the risk of endometrial cancer (OR = 1.20, 95% CI = 0.83 to 1.74) compared with the T allele, but no statistical difference was found (P = 0.3333). The homozygous GG genotype was also associated with postmenopausal status and type I endometrial cancer (P = 0.0306 and 0.0326, respectively). There was no significant difference in the genotype or allele prevalence between control subjects and cervical or ovarian cancer patients. These results suggest that homozygous GG genotype of MDM2-SNP309 may be a risk factor for postmenopausal and type I endometrial cancer in a Japanese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.